News

Dynavax’s GMP manufacturing facility in Dusseldorf, Germany has been approved for the commercial production of hepatitis B surface antigen, a key component of Heplisav, an investigational adult hepatitis

Pacific Beach BioSciences has granted non-exclusive rights to a pharmaceutical company for the use of one of its anti-fungal compounds required for the manufacturing of a clinical stage

Skystar has purchased an exclusive aquaculture vaccine technology from and signed a collaborative research and development agreement with China’s Fourth Military Medical University (FMMU) for RMB 8m, granting

Lentigen has received a National Institutes of Health (NIH) small business innovation research (SBIR) grant for a program on ‘A Novel Method of Generating Hepatitis C virus (HCV)

Nabi Biopharmaceuticals (Nabi) has initiated a Phase I/II clinical trial for two of the antigens in the PentaStaph vaccine candidate, which is now owned by GlaxoSmithKline Biologicals (GSK).

BioSystem Development has released the AssayMAP MAb Titer Assay for measuring antibody product concentrations (or titers) in bioprocess samples. Antibody titer assays are a critical bottleneck in biotherapeutic

Pharming has confirmed its interactions in a pre-BLA meeting with the FDA on a proposed marketing application (BLA or Biologics License Application) to obtain marketing approval for Rhucin

Clinuvel Pharmaceuticals had obtained positive results from an experimental trial evaluating the photoprotective effect of Afamelanotide in 16 patients. The objective of this pilot Phase II trial was

Oxagen has completed the recruitment for its double blind, randomised, placebo controlled Phase IIb clinical trial in asthma with OC000459, its oral CRTH2 (DP2) antagonist. The study, which